Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio, a clinical-stage oncology company focused on developing therapies for oncogene amplified cancers, announced an upcoming poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts. The presentation will feature groundbreaking research on the synergistic effects of their selective ribonucleotide reductase (RNR) inhibitor, BBI-825, combined with the selective checkpoint kinase 1 (CHK1) inhibitor, BBI-355. This combination aims to target unique dependencies prevalent in oncogene amplified cancers, with the presentation titled "Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers." The abstract number for this presentation is LB-A022, and it is scheduled for the Poster Session A on October 23, 2025, from 12:30 to 4:00 PM ET at Level 2, Exhibit Hall D.

Boundless Bio is pioneering the exploration of extrachromosomal DNA (ecDNA), a factor implicated in oncogene amplification affecting 14% to 17% of cancer patients. Their lead pipeline candidates include BBI-355 and BBI-825, which are currently undergoing evaluation in the company’s phase 1/2 POTENTIATE clinical trial. In addition to these, Boundless Bio is also advancing BBI-940, a potential first-in-class orally bioavailable Kinesin degrader, through IND-enabling studies. Headquartered in San Diego, California, Boundless Bio aims to revolutionize cancer treatment for patients with historically challenging oncogene amplified tumors, signaling significant strides in the oncology landscape. For more information, visit their official website or follow them on social media platforms.

Boundless Bio (Nasdaq: BOLD) is poised to capture the attention of investors as it prepares for a significant presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Scheduled for October 23, 2025, this event will showcase the company’s innovative approach to treating oncogene amplified cancers, particularly through their synergistic combination of BBI-825, a selective RNR inhibitor, and BBI-355, a CHK1 inhibitor.

As a clinical-stage oncology firm, Boundless Bio focuses on ecDNA, which plays a critical role in the amplification of oncogenes in about 14% to 17% of cancer patients. This research focus positions the company at the forefront of an important and underserved market segment. Investors should take note of not only the scientific merit of its work but also the potential market implications, given the high unmet need in this therapeutic area.

The upcoming poster presentation (Abstract Number: LB-A022) is an opportunity for the company to validate its approach, potentially catalyzing investor interest and encouraging institutional buy-in. The format of the session allows for direct engagement with key stakeholders including researchers, oncologists, and potential investors, which could enhance BOLD’s visibility among influential decision-makers in oncology.

Strategically, investors may consider initiating positions ahead of the conference to capitalize on potential positive momentum. However, it is crucial to exercise cautious optimism, as clinical-stage biopharmaceuticals can experience volatility around presentation events and clinical data releases. Monitoring the response to the presentation will be essential; positive feedback from peers could lead to stock appreciation, whereas any concerns could have the opposite effect.

In conclusion, Boundless Bio presents a compelling opportunity within the oncology sector, and the upcoming conference is a key inflection point that merits close attention from investors.